Bipartisan legislation to cap the cost of insulin at $35 for people with private health insurance advanced through a key Senate committee Wednesday, but its future remains uncertain. The measure cleared the Senate Health, Education, Labor and Pensions Committee by a bipartisan 17-5 vote, with six Republicans joining every Democrat on the panel. Notably,...